Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis

Company Overview

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $1.30 to $1.62
• 52-Week Range: $0.94 to $5.70
• Volume: 900 shs
• Average Volume: 98,414 shs
• Market Capitalization: $1.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OASM Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oasmia Pharmaceutical AB (publ) investors own include Protalix BioTherapeutics (PLX), Amarin (AMRN), Bristol-Myers Squibb (BMY), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), VBI Vaccines (VBIV) and Verastem (VSTM).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OASM
• CIK: 1607245
• Web: www.oasmia.com
• Phone: (461) 850-5440
• Fax: N/A
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.95 million
• Net Margins: -8,633.64%
• Pretax Margin: N/A
• Return on Equity: -43.94%
• Return on Assets: -28.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.80
• Quick Ratio: 0.73

Sales & Book Value

• Annual Sales: $220 thousand
• Price / Sales: 6.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.63 per share
• Price / Book: 0.03

Miscellaneous

• Outstanding Shares: 74,967,000
• Free Float: N/A
• Market Cap: $1.50 million
• Optionable: Not Optionable
• Beta: 0.96